Nanosized Transferosome-Based Intranasal In Situ Gel for Brain Targeting of Resveratrol: Formulation, Optimization, In Vitro Evaluation, and In Vivo Pharmacokinetic Study.

Clics: 430
ID: 1800
2019
Metricas de Calidad y Rendimiento del Articulo
Calidad General
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
Evaluacion de Calidad por IA
No analizado
Readership in this journal
Emerging

Ranked #6 of 79 articles by views in aaps pharmscitech

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Resumen
Resveratrol (RES) is a potent antioxidant used for the management of several central nervous system diseases. RES bioavailability is less than 1 owing to its low solubility and extensive intestinal and hepatic metabolism. The aim of the study was to enhance RES bioavailability through developing intranasal transferosomal mucoadhesive gel. Reverse evaporation-vortexing sonication method was employed to prepare RES-loaded transferosomes. Transferosomes were developed via 3 definitive screening design, using soya lecithin, permeation enhancers, and surfactants. The optimized formula displayed spherical shape with vesicle size of 83.79 ± 2.54 nm and entrapment efficiency (EE%) of 72.58 ± 4.51%. Mucoadhesive gels were prepared and evaluated, then optimized RES transferosomes were incorporated into the selected gel and characterized using FTIR spectroscopy, in vitro release, and ex vivo permeation study. Histopathological examination of nasal mucosa and in vivo pharmacokinetic study were conducted. In vitro drug release from transferosomal gel was 65.87 ± 2.12% and ex vivo permeation was 75.95 ± 3.19%. Histopathological study confirmed the safety of the optimized formula. The C of RES in the optimized RES trans-gel was 2.15 times higher than the oral RES suspension and AUC increased by 22.5 times. The optimized RES trans-gel developed intranasal safety and bioavailability enhancement through passing hepatic and intestinal metabolism.
Clave de Referencia
salem2019nanosizedaaps Use esta clave para autocitar en el manuscrito mientras usa SciMatic Manuscript Manager o Thesis Manager
Autores Salem, Heba F;Kharshoum, Rasha M;Abou-Taleb, Heba A;Naguib, Demiana M;
Revista aaps pharmscitech
Ano 2019
DOI
10.1208/s12249-019-1353-8
URL
Palabras Clave Palabras clave no encontradas

Citas

No se encontraron citas. Para agregar una cita, contacte al administrador en info@scimatic.org

Comentarios

Aun no hay comentarios. Sea el primero en comentar este articulo.